A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD)

drug protocol number
BAY 94-8862 17530
drug sponsor
Bayer
drug study
Finerenone
drug trial site
King Abdulaziz University Hospital (Jeddah)
drug status
Terminated
drug phase